The release of the REMS failed to create a change in search volume for the majority of the drugs. This may be due to prior elevated interest as the result of previous safety alerts or may be an indication that the REMS fails to create increased awareness of the risks of the drug. Further analysis of FDA safety alerts or change point analysis may provide a greater understanding of the effect of various risk management methods.